Gesundes Kinzigtal

Gesund.ai Joins White House CancerX Initiative to End Cancer As We Know It

Retrieved on: 
목요일, 10월 5, 2023
Patent, Partnership, Multi, Drug development, Yale Physician Associate Program, Medicine, AI, Risk, Dime, Cancer Moonshot, Safety, Digital, Cancer, Office of the National Coordinator for Health Information Technology, FDA, Doctor of Philosophy, Patient safety, White House Initiative on Asian Americans, Native Hawaiians, and Pacific Islanders, Assistant, Health equity, H. Lee Moffitt Cancer Center & Research Institute, Life, Patient, White House, Medical device, Pharmaceutical industry, Health, Gesundes Kinzigtal

CAMBRIDGE, Mass., Oct. 5, 2023 /PRNewswire/ -- Gesund.ai, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced it has joined the White House Cancer Moonshot — CancerX — joining hundreds of public, private, and non-governmental organizations to deliver progress on the mission to end cancer as we know it. Gesund will contribute its expertise as a compliant AI Factory that allows companies to train and validate models in order to then secure FDA clearance. As the industry's leading independent third party AI validator, Gesund uses its proprietary technology and partnerships to audit and validate each model to ensure cutting-edge medical AI products can be trusted and are safe for all.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 5, 2023 /PRNewswire/ -- Gesund.ai, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced it has joined the White House Cancer Moonshot — CancerX — joining hundreds of public, private, and non-governmental organizations to deliver progress on the mission to end cancer as we know it.
  • CancerX is the inaugural project in The White House's national Cancer Moonshot initiative.
  • "We are honored to partner with Gesund.ai and leverage digital innovation in the fight against cancer," said Edmondo Robinson, Chief Digital Officer of Moffitt Cancer Center.
  • This partnership offers the potential to bridge the gap between the world of cancer care today and our vision for CancerX and the future."